Sanofi ends deal with Exelixis on PI3K inhibitors
This article was originally published in Scrip
Executive Summary
A day after bagging a multimillion dollar deal with Merck, Exelixis revealed in a filing with the Securities and Exchange Commission that it had ended its 2009 collaboration with Sanofi, in which the firms were partnering to discover inhibitors of phosphoinositide-3 Kinase (PI3K) alpha and beta.